| Code | CSB-RA023981MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BAT-6062, designed to specifically bind TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding to its ligand OX40L, TNFRSF4 enhances immune responses by promoting effector and memory T cell differentiation while inhibiting regulatory T cell function. This receptor is implicated in various pathological conditions including autoimmune diseases, allergic inflammation, and cancer, where it serves as a key checkpoint molecule modulating antitumor immunity.
BAT-6062 is an TNFRSF4 agonistic antibody developed by Biothea Biotech. It specifically binds to and activates the TNFRSF4 signaling pathway, providing "co-stimulatory signals" to T cells, enhancing their activation, proliferation, survival and function, thereby strengthening the anti-tumor immune response. This biosimilar provides researchers with a reliable tool for studying OX40 biology, examining T cell costimulation mechanisms, and exploring therapeutic strategies targeting TNFRSF4 in immuno-oncology and autoimmune disease models. The antibody supports diverse experimental approaches aimed at understanding immune checkpoint modulation and developing novel immunotherapeutic interventions.
There are currently no reviews for this product.